[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Laura J. Schumacher net worth and biography

Laura Schumacher Biography and Net Worth

Vice Chairman of AbbVie

Laura Schumacher is Vice Chairman, External Affairs and Chief Legal Officer, a member of the executive leadership team, and responsible for global legal, health economics outcomes research, corporate brand and communications and government affairs.

Prior to AbbVie’s separation from Abbott, Ms. Schumacher served as Executive Vice President, General Counsel. Both at Abbott and AbbVie, Ms. Schumacher has led Business Development and Ventures & Early Stage Collaborations. Ms. Schumacher joined Abbott as a litigation attorney, held various leadership positions in the company, and was appointed Senior Vice President, General Counsel in 2005. Prior to joining Abbott, Ms. Schumacher was an associate attorney with the law firm Schiff, Hardin & Waite in Chicago, Illinois.

Ms. Schumacher serves on the Board of Directors of General Dynamics Corporation, the Board of Trustees for Ronald McDonald House Charities and the Notre Dame Law School Advisory Board. She is also a member of the National Association of Corporate Directors, American Bar Association and the Economic Club of Chicago.

She earned a bachelor's degree in business administration from the University of Notre Dame and a juris doctorate from the University of Wisconsin at Madison, U.S.A.

What is Laura J. Schumacher's net worth?: The estimated net worth of Laura J. Schumacher is at least $27.65 million as of September 16th, 2019. Ms. Schumacher owns 164,838 shares of AbbVie stock worth more than $27,649,926 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Schumacher may own. Learn More about Laura J. Schumacher's net worth.
How do I contact Laura J. Schumacher?: The corporate mailing address for Ms. Schumacher and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Laura J. Schumacher's contact information.
Has Laura J. Schumacher been buying or selling shares of AbbVie?: Laura J. Schumacher has not been actively trading shares of AbbVie in the last ninety days. Most recently, Laura J. Schumacher sold 181,670 shares of the business's stock in a transaction on Friday, December 17th. The shares were sold at an average price of $130.24, for a transaction totalling $23,660,700.80. Learn More on Laura J. Schumacher's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 12 times. They sold a total of 735,581 shares worth more than $130,132,002.24. The most recent insider tranaction occured on August, 5th when Chairman Richard A Gonzalez sold 66,500 shares worth more than $12,403,580.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 8/5/2024.

Laura J. Schumacher Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2021	Sell	181,670	$130.24	$23,660,700.80
9/16/2019	Buy	25,000	$70.42	$1,760,500.00	164,838
3/14/2019	Sell	25,000	$80.00	$2,000,000.00	139,838
12/28/2018	Sell	25,000	$90.00	$2,250,000.00
12/28/2018	Sell	25,000	$90.00	$2,250,000.00	134,322
12/4/2018	Sell	94,140	$93.58	$8,809,621.20	192,398
3/1/2018	Sell	25,000	$117.85	$2,946,250.00	123,317
12/15/2017	Sell	145,510	$96.71	$14,072,272.10
6/14/2017	Sell	79,800	$70.00	$5,586,000.00	187,625
3/10/2017	Sell	40,000	$65.26	$2,610,400.00	147,415
9/7/2016	Sell	50,000	$65.00	$3,250,000.00	144,138
6/24/2016	Sell	186,106	$60.03	$11,171,943.18	260,438
3/8/2016	Sell	25,000	$56.09	$1,402,250.00	199,238
3/2/2015	Sell	25,000	$60.30	$1,507,500.00

Laura J. Schumacher Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $167.74

$165.65

$167.91

50 Day Range

MA: $190.25

$164.91

$203.87

2 Week Range

Now: $167.74

$137.65

$207.32

Volume

7,133,346 shs

Average Volume

5,488,950 shs

Market Capitalization

$296.42 billion

P/E Ratio

58.24

Dividend Yield

3.76%

Beta

0.63